Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Let’s keep it simple: If you want to delay Alzheimer’s onset, focus on walking and adding nutritious foods, such as walnuts, ...

Researchers at the UConn Center on Aging have uncovered causal links between depression and Alzheimer’s disease and related ...

TORONTO -- Blood tests for Alzheimer's disease biomarkers can be used clinically -- and can replace expensive brain scans and ...

New tests and new treatments are presenting more options for certain patients with Alzheimer's disease. “Today a confluence ...

Families across Georgia are finding new hope in the fight against Alzheimer’s disease, thanks to promising treatments at ...

Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

The idea that herpes infections trigger or contribute to Alzheimer's disease has been gaining favor among some scientists, ...

TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...